Q-omics provides the consensus-scored RNF180 profile across patient tissues and cancer cell-line models. RNF180 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RNF180 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, RNF180 RNA expression shows 20,029 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, KIRC, and PDAC as cancer lineages where RNF180 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF180 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF180 survival associations across molecular data types. RNF180 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF180 RNA expression–survival associations across cancer types. High RNF180 expression shows unfavorable associations in COAD and STAD, but favorable associations in ACC, KIRC, BRCA and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RNF180 RNA expression.
This table summarizes RNF180 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RNF180. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF180 shows lower tumor expression in KIRC, BLCA, LUAD, THCA, HNSC and LUSC. The KIRC box plot shows higher RNF180 RNA expression in normal versus tumor tissue (log2 FC = −1.347, t-test p < 0.001).
This table shows molecular features associated with RNF180 in patient tissues and cancer cell lines. In patient samples, RNF180 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF180 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SKIN.
